- Home
- DMAC vs NVX Comparison
DMAC vs NVX Comparison
Compare DMAC & NVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- NVX
- Stock Information
- Founded
- DMAC 2000
- NVX 2012
- Country
- DMAC United States
- NVX Australia
- Employees
- DMAC N/A
- NVX N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- NVX Industrial Machinery/Components
- Sector
- DMAC Health Care
- NVX Miscellaneous
- Exchange
- DMAC Nasdaq
- NVX Nasdaq
- Market Cap
- DMAC 178.0M
- NVX 168.6M
- IPO Year
- DMAC N/A
- NVX N/A
- Fundamental
- Price
- DMAC $3.76
- NVX $1.14
- Analyst Decision
- DMAC Strong Buy
- NVX
- Analyst Count
- DMAC 2
- NVX 0
- Target Price
- DMAC $8.00
- NVX N/A
- AVG Volume (30 Days)
- DMAC 307.4K
- NVX 62.8K
- Earning Date
- DMAC 08-06-2025
- NVX 01-01-0001
- Dividend Yield
- DMAC N/A
- NVX N/A
- EPS Growth
- DMAC N/A
- NVX N/A
- EPS
- DMAC N/A
- NVX N/A
- Revenue
- DMAC N/A
- NVX $5,854,424.00
- Revenue This Year
- DMAC N/A
- NVX $66.66
- Revenue Next Year
- DMAC N/A
- NVX $2,366.64
- P/E Ratio
- DMAC N/A
- NVX N/A
- Revenue Growth
- DMAC N/A
- NVX N/A
- 52 Week Low
- DMAC $2.80
- NVX $0.81
- 52 Week High
- DMAC $6.82
- NVX $2.73
- Technical
- Relative Strength Index (RSI)
- DMAC 47.18
- NVX 52.40
- Support Level
- DMAC $3.48
- NVX $0.99
- Resistance Level
- DMAC $3.99
- NVX $1.19
- Average True Range (ATR)
- DMAC 0.32
- NVX 0.06
- MACD
- DMAC -0.00
- NVX 0.01
- Stochastic Oscillator
- DMAC 41.01
- NVX 68.18
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About NVX NOVONIX Limited American Depository Shares
NOVONIX Ltd operates in the lithium-ion battery industry. The company has three operating segments namely Graphite Exploration, Battery Technology, and Battery Materials. Graphite Exploration segment is engaged in the exploration and development of high-grade flake graphite deposits. The Battery Technology segment develops battery cell testing equipment and carries out research and development in battery development. The Battery Materials segment develops and manufactures battery anode materials. The Battery Technology segment generates maximum revenue for the company.